RIGL

Rigel Pharmaceuticals Stock Analysis

AI Rating

Great
  • Quality9/10
  • Growth↑ 9/10
  • Value↑ 5/10
Rigel Pharmaceuticals sales and earnings growth
RIGL Growth
Great
  • Revenue Y/Y↑ 47.61%
  • EPS Y/Y↑ 863.33%
  • FCF Y/Y↑ 123.74%
Rigel Pharmaceuticals gross and profit margin trends
RIGL Profitability
Great
  • Gross margin ↑ 93.40%
  • EPS margin↑ 121.50%
  • ROIC 5Y↑ 29.96%
Rigel Pharmaceuticals net debt vs free cash flow
RIGL Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.3
  • Interest coverage↑ 18.7

Rigel Pharmaceuticals stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

↗ More Biotechnology stocks